# Q4 2023

# **New Zealand Crown Financial Institutions:**

New Zealand Superannuation Fund Accident Compensation Corporation Government Superannuation Fund National Provident Fund

\*Companies represented in this report may not be held by each Crown Financial Institution.

The purpose of the **reo**\*(responsible engagement overlay) service is to engage with companies held in portfolios with a view to promoting the adoption of better environmental, social and governance (ESG) practices. The **reo**\* approach focuses on enhancing long-term investment performance by making companies more commercially successful through safer, cleaner, and more accountable operations that are better positioned to deal with ESG risks and opportunities.

#### **Engagement this quarter**

Engagement	Companies Engaged	Milestones achieved	Countries covered
202	174	56	24

# **Companies engaged by region**



#### **Engagement by theme \***



#### Milestones achieved by theme






<sup>\*</sup> Companies may have been engaged on more than one issue.

# **Engagements and Sustainable Development Goals (SDGs)**


The 17 Sustainable Development Goals (SDGs) were developed by the UN and cross-industry stakeholders with a view to providing a roadmap towards a more sustainable world.

We use the detailed underlying SDG targets to frame company engagement objectives, where relevant, as well as to articulate the positive societal and environmental impacts of engagement. Engagements are systematically captured at a target level, to enable greater accuracy and achieve higher impact.


# **Engagement: SDG level**



# **Engagement: SDG target level**




# **Milestone: SDG level**



# \*Other represents SDG targets less than 2% of the relevant SDG Goal.

# Milestone: SDG target level







































# **Engagement case studies**

Company: GSK PLC Country: United Kingdom Sector: Health Care **Priority Company: -ESG Risk Rating:** Response to engagement: Good Theme: Public Health Issue: Diversity in clinical trials at GSK SDG: 3.8

#### **Background**

GSK is a global bio-pharmaceutical company which manufactures innovative medicines and vaccines. Upcoming US regulatory requirements due to take effect in 2024 will push the industry to include diversity planning in their trial protocol or justify why this is not necessary. In our view, being under-prepared for this might result in novel drugs and therapies not being approved by the FDA, which poses a very material risk to drug manufacturers and Contract Research Organizations (CROs). As part of our diversity in clinical trials engagement project, we organized a call with GSK's Senior Vice President of Global Clinical Operations to learn more about the company's work on diversity in clinical trials and preparations for stricter regulation.

#### **Action**

We discussed the upcoming regulatory requirements on diversity in clinical trials and how GSK prepares for compliance. The company has a dedicated team that works on diversity in clinical trials, which ultimately falls under the Chief Scientific Officer. While work on trial diversity costs time and effort, GSK considers this a continuous learning curve for the company. They stressed that this is the right thing to do for patients and communities and that financially, the cost of getting it wrong will be more substantial. They also consider it a crucial part of their ambition to reach 2.5 billion patients by the end of 2030. The company shared a number of insightful case studies, for instance on how it works together with patient advocacy groups to assess and better understand patient needs as well as increasing the availability of Decentralized Clinical Trials (DCT). Finally, GSK shared more insight into how they collaborate with CROs, that they expect these to adhere to GSK's third-party vendor rules and that GSK is not interested in working with CROs who do not work on improving diversity in clinical trials.

#### Verdict

The key take-away from this conversation was that diversity in clinical trials is increasingly embedded in the company-wide strategy. GSK feels confident about their preparedness for regulatory requirements, having made efforts to increase diversity in clinical trials for over 15 years. This is evidenced by successful progress on their target to have 100% of 2023 phase III trials contain a proactive strategy to enroll appropriately diverse trial participants, consistent with the disease epidemiology. We consider GSK a leader in this space and will monitor further developments.

# **Engagement case studies**

Company: Adobe Inc **Country:** United States Sector: Information Technology **Priority Company: -ESG Risk Rating:** Response to engagement: Good Theme: Human Rights Issue: Adobe's leading approach to Responsible Al SDG: 10.3 (È)

#### **Background**

Adobe is one of the largest software companies in the world, offering a suite of products and services used by creative professionals, businesses, and customers to create, manage, measure, optimise content and experiences. Artificial Intelligence (AI) is embedded in many of its offerings and has the power to drive greater innovation and monetization opportunities. With this in mind, their approach to Responsible AI was high on our engagement agenda.

#### Action

We held a dialogue with Adobe's Investor Relations and General Counsel to learn more about the company's approach to Responsible Al. We asked about the company's governance approach as well as requesting further details on its impact assessment. We also discussed areas of biggest potential risks and how the company approaches mitigating them. Several years ago, Adobe formed an AI ethics governance committee which is responsible for conducting an AI ethics review every time an AI feature is proposed. It involves identifying potential harm and bias and multiple tests to minimize and eliminate these risks where possible. In order to measure the success of its efforts to mitigate Al bias or harm, the company tracks the percentage of outputs that are categorised as harmful. Adobe provided context about its Firefly tool (its generative machine learning model used in the field of design) which is trained solely on its licensed assets in order to reduce copyright related risks. It also mentioned that a wide variety of teams are involved in the oversight of testing to ensure diversity of perspectives are taken into account. Beyond social issues, the risks on the environmental side in relation to Al are believed to be more nascent. Nonetheless, the topic is addressed at the Board level when considering the potential impact on its net zero commitment.

#### Verdict

Overall, it is clear the company has been ahead of the curve on Responsible Al which presents a revenue opportunity, competitive advantage, and the opportunity for proactive risk mitigation. We were encouraged by the constructive dialogue, using the opportunity to better understand Adobe's leading approach. We will take some of these findings and outcomes into our internal Responsible Al assessment framework as Responsible Al remains a key topic for 2024. Engagements such as these are key for us to continuously evolve our understanding of how companies are thinking about Responsible AI and to learn and share good practices as we encourage industry-wide improvement.

# **Engagement case studies**

Company: ArcelorMittal SA Country: Luxembourg Sector: Materials **Priority Company: -ESG Risk Rating:** Response to engagement: Good Theme: Human Rights, Labour Standards Issue: Engaging on worker safety after the deadly fire in Kazakhstan SDG: 8.8

#### **Background**

ArcelorMittal is the second largest steel-producer globally, with manufacturing facilities in 16 countries and customers in 155. 46 of ArcelorMittal's (MT) employees were killed in a fire at its Kostenko coal mine in Kazakhstan which was triggered by a methane-gas explosion on October 28th, 2023. The explosion is the most severe industrial accident in Kazakhstan's independent history and triggered the nationalization of all MT's assets in the country, consisting of 8 coal mines, 4 iron ore mines and 1 steel plant.

#### Action

MT reached out to us following the accident to explain the remediation actions taken, and to outline what went wrong along with the lessons learnt. We have previously spoken to the company about its chequered safety record in Kazakhstan, as there have been consistent indications that the company is not handling occupational safety effectively for example with 14 fatalities in 2022 and 4 fatalities before October 2023. MT quickly outlined the remediation steps taken after the accident, including providing immediate support for families, such as a payment equivalent to a 10-year salary, payment for children's education up to the age of 23 and repayment of all personal loans of the families impacted. Regarding what went wrong, MT highlighted the 'complex' geology of the region as well as the 'risktaking culture' as exacerbating risks. We challenged the company on this, as these are in no ways risks that we believe should have been outside of MT's due diligence and safety reviews - as it stands, we view these two explanations as inadequate at justifying what went wrong, particularly considering the scale of the accident and the endemic safety issues in the region. We requested evidence of how MT will ensure that its 33,000 employees- who are now being transferred to a nationalized company - will not be exposed to even worse work conditions. The company state they want to ensure a good legacy for MT in the region, however this will be a challenge, with the Prime Minister of Kazakhstan stating on the day of the disaster that MT is the "worst" investor in Kazakhstan's independent history.

#### Verdict

We are disappointed by the explanations provided by MT on what went wrong, particularly considering the safety record in the region which should have provided ample warning of the need for significant improvement on safety monitoring and procedures. MT state more information will be provided after the ongoing third-party audit of the whole company's safety practices is published, due in mid-2024. We will re-engage the company on safety after its publication.

# **Appendix**





































SDG	Target	Target Summary
■ SDG1	1.1	Eradicate poverty and ensure a living wage for all
SDG2	2.1	End hunger and ensure access to safe and nutritious food
■ SDG3	3.8	Access to medicines and health-care
■ SDG3	3.9	Reduce deaths and illnesses from pollution and contamination
■ SDG5	5.1	End all forms of discrimination against women and girls
■ SDG5	5.5	Ensure full equality of opportunity for women, including at leadership levels
SDG6	6.1	Achieve universal access to safe & affordable drinking water
■ SDG6	6.3	Improve water quality by reducing pollution
■ SDG6	6.4	Increase water-use efficiency to address water scarcity
SDG7	7.2	Substantially increase the global share of renewable energy
SDG7	7.3	Double the global rate of improvement in energy efficiency
■ SDG8	8.2	Achieve greater productivity through innovation.
■ SDG8	8.3	Promote development-oriented policies
■ SDG8	8.5	Achieve full and productive employment for all
■ SDG8	8.7	Eradicate forced labour, modern slavery & human trafficking
■ SDG8	8.8	Protect and promote safe working environments for all workers
■ SDG8	8.10	Increase access to finance
SDG9	9.1	Develop resilient and sustainable infrastructure
■ SDG9	9.4	Upgrade and retrofit industries to increase sustainability
■ SDG9	9.c	Ensure universal and affordable access to ICT
■ SDG10	10.1	Achieve a higher rate of income growth for the bottom 40%
■ SDG10	10.2	Empower and promote inclusivity for all
■ SDG10	10.3	Ensure equal opportunity and legislation for all
■ SDG10	10.4	Adopt policies to progressively achieve greater equality
SDG11	11.2	Provide access to safe and affordable transport systems
SDG12	12.2	Sustainably manage and make efficient use of natural resources
■ SDG12	12.4	Manage chemical usage and waste throughout their life cycle

# **Appendix (continued)**







































SDG	Target	Target Summary
SDG12	12.5	Reduce waste through prevention, reduction, recycling and reuse
SDG12	12.6	Encourage companies to adopt sustainable practices and enhance ESG reporting
SDG12	12.7	Promote sustainable procurement practices
■ SDG13	13.1	Strengthen adaptive capacity to climate-related events
■ SDG13	13.2	Integrate climate change plans into policies and strategies
■ SDG13	13.a	Address climate change mitigation for developing countries
SDG14	14.1	Prevent and reduce marine pollution of all kinds
■ SDG15	15.1	Ensure sustainable usage of terrestrial freshwater ecosystems
■ SDG15	15.2	Promote the implementation of sustainable management of forests
■ SDG15	15.5	Take urgent action to reduce degradation of natural habitats
■ SDG16	16.5	Reduce corruption and bribery in all their forms
■ SDG16	16.6	Develop effective, accountable and transparent institutions
■ SDG16	16.b	Promote non-discrimination laws for sustainable development

investors only. Financial promotions are issued for marketing and information purposes; in the United Kingdom by Columbia Threadneedle Management Limited, which is authorised and regulated by the Financial Conduct Authority; in the EEA by Columbia Threadneedle Netherlands B.V., which is regulated by the Dutch Authority for the Financial Markets (AFM); and in Switzerland by Columbia Threadneedle Management (Swiss) GmbH, acting as representative office of Columbia Threadneedle Management Limited. In the Middle East: This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA). For Distributors: This document is intended to provide distributors with information about Group products and services and is not for further distribution. For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparties and no other Person should act upon it. 228126 (07/22). This item is approved for use in the following countries; AT, AU, DK, FR, DE, NL, PT, CH, UK, US, NZ, CA, KR.